Ken Griffin Genmab A/S Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Genmab A/S stock. As of the latest transaction made, Citadel Advisors LLC holds 48,200 shares of GMAB stock, worth $979,905. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,200

Previous 15,700 207.01%

Holding current value

$979,905

Previous $327,000 188.38%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$18.69 - $24.14 $24.9 Million - $32.2 Million	1,334,510 Added 43.16%	4,426,654 $86.7 Million
Q4 2024 Feb 14, 2025	BUY	$20.02 - $24.15 $35.9 Million - $43.3 Million	1,792,288 Added 137.88%	3,092,144 $64.5 Million
Q3 2024 Nov 14, 2024	BUY	$23.84 - $28.48 $690,597 - $825,008	28,968 Added 2.28%	1,299,856 $31.7 Million
Q2 2024 Aug 14, 2024	BUY	$25.13 - $30.27 $30.7 Million - $37 Million	1,222,750 Added 2540.09%	1,270,888 $31.9 Million
Q1 2024 May 15, 2024	SELL	$26.43 - $32.77 $2.84 Million - $3.52 Million	-107,383 Reduced 69.05%	48,138 $1.44 Million
Q4 2023 Feb 14, 2024	SELL	$27.94 - $35.44 $2.5 Million - $3.17 Million	-89,390 Reduced 36.5%	155,521 $4.95 Million
Q3 2023 Nov 14, 2023	SELL	$35.27 - $42.24 $995,425 - $1.19 Million	-28,223 Reduced 10.33%	244,911 $8.64 Million
Q2 2023 Aug 14, 2023	SELL	$37.4 - $42.94 $5.94 Million - $6.82 Million	-158,719 Reduced 36.75%	273,134 $10.4 Million
Q1 2023 May 15, 2023	BUY	$34.88 - $43.22 $1.07 Million - $1.33 Million	30,699 Added 7.65%	431,853 $16.3 Million
Q4 2022 Feb 14, 2023	BUY	$33.8 - $47.06 $2.89 Million - $4.03 Million	85,560 Added 27.11%	401,154 $17 Million
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $2.4 Million - $28.5 Million	76,206 Added 31.83%	315,594 $10.1 Million
Q2 2022 Aug 15, 2022	BUY	$26.83 - $38.57 $3.11 Million - $4.47 Million	115,930 Added 93.9%	239,388 $7.78 Million
Q1 2022 May 16, 2022	BUY	$30.95 - $39.68 $3.17 Million - $4.06 Million	102,419 Added 486.81%	123,458 $4.47 Million
Q3 2021 Nov 15, 2021	BUY	$41.55 - $48.72 $31,079 - $36,442	748 Added 3.69%	21,039 $919,000
Q2 2021 Aug 16, 2021	SELL	$32.88 - $44.57 $7.2 Million - $9.75 Million	-218,841 Reduced 91.51%	20,291 $828,000
Q4 2020 Feb 16, 2021	SELL	$33.66 - $40.76 $1.47 Million - $1.78 Million	-43,578 Reduced 15.41%	239,132 $9.72 Million
Q3 2020 Nov 16, 2020	BUY	$33.07 - $38.68 $1 Million - $1.17 Million	30,339 Added 12.02%	282,710 $10.4 Million
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $4.56 Million - $7.71 Million	227,512 Added 915.21%	252,371 $8.55 Million
Q1 2020 May 15, 2020	SELL	$17.15 - $25.22 $7.17 Million - $10.5 Million	-417,900 Reduced 94.39%	24,859 $527,000
Q4 2019 Feb 14, 2020	SELL	$18.88 - $24.14 $13.5 Million - $17.2 Million	-714,061 Reduced 61.73%	442,759 $9.89 Million
Q3 2019 Nov 14, 2019	BUY	$18.0 - $21.38 $20.8 Million - $24.7 Million	1,156,820 New	1,156,820 $23.4 Million

Others Institutions Holding GMAB

# of Institutions

247

Shares Held

66.2M

Call Options Held

729K

Put Options Held

398K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.4B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account